"Cystic fibrotics could survive cholera, choleraics could survive cystic fibrosis"; hypothesis that explores new horizons in treatment of cystic fibrosis

Medical Hypotheses

Volumn 85, Issue 6, 2015, Pages 715-717

  Azimi, Arsalan ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CHOLERA TOXIN; IMMUNOLOGICAL ADJUVANT;

AIRWAY OBSTRUCTION; ARTICLE; BACTERIAL GROWTH; CHOLERA; CYSTIC FIBROSIS; DISEASE ASSOCIATION; ENZYME INACTIVATION; GROWTH INHIBITION; HUMAN; IMMUNE BOOSTER; IMMUNOMODULATION; MUCOCILIARY CLEARANCE; MUCODILUTER; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT MUCOSA; RESPIRATORY TRACT PARAMETERS; SURVIVAL; BIOLOGICAL MODEL; BREATHING MECHANICS; DRUG EFFECTS; EVIDENCE BASED MEDICINE; LUNG; MICROBIOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CHOLERA; CHOLERA TOXIN; CYSTIC FIBROSIS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG; MODELS, BIOLOGICAL; RESPIRATORY MECHANICS; TREATMENT OUTCOME;

EID: 84947438167     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.10.023     Document Type: Article

References (15)

1. Rodman D.M., Zamudio S. The cystic fibrosis heterozygote - advantage in surviving cholera?. Med Hypotheses 1991, 36(3):253-258. PubMed PMID: 1724059.
2. Goodman B.E., Percy W.H. CFTR in cystic fibrosis and cholera: from membrane transport to clinical practice. Adv Physiol Educ 2005, 29(2):75-82. PubMed PMID: 15905150.
3. Juzych N.S., Resnick B., Streeter R., Herbstman J., Zablotsky J., Fox M., et al. Adequacy of state capacity to address noncommunicable disease clusters in the era of environmental public health tracking. Am J Public Health 2007, 97(Suppl. 1):S163-S169. PMCID: PMC1854996. 10.2105/AJPH.2006.096453.
4. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin. Nature 1998, 391(6670):851.
5. Lycke N.Y. Cholera toxin promotes B cell isotype switching by two different mechanisms. cAMP induction augments germ-line Ig H-chain RNA transcripts whereas membrane ganglioside GM1-receptor binding enhances later events in differentiation. J Immunol 1993, 150(11):4810-4821.
6. Gagliardi M.C., De Magistris M.T. Maturation of human dendritic cells induced by the adjuvant cholera toxin: role of cAMP on chemokine receptor expression. Vaccine 2003, 21(9-10):856-861.
7. Eriksson K., Fredriksson M., Nordström I., Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect Immun 2003, 71(4):1740-1747. PubMed PMID: 12654787; PubMed Central PMCID: PMC152034.
8. Bromander A., Holmgren J., Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol 1991, 146(9):2908-2914.
9. Chen K.S., Strober W. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response. Eur J Immunol 1990, 20(2):433-436.
10. Abraham E., Robinson A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia. Vaccine 1991, 9(10):757-764.
11. Walsh E.E. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine 1993, 11(11):1135-1138.
12. Yamamoto M., McDaniel L.S., Kawabata K., Briles D.E., Jackson R.J., McGhee J.R., et al. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun 1997, 65(2):640-644. PubMed Central PMCID: PMC176108.
13. Cong Y., Oliver A.O., Elson C.O. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur J Immunol 2001, 31(1):64-71. PubMed PMID: 11169439.
14. Hoffman L.R., Ramsey B.W. Cystic fibrosis therapeutics: the road ahead. Chest 2013, 143(1):207-213. PubMed PMID: 23276843; PubMed Central PMCID: PMC3610617. 10.1378/chest.12-1639.
15. Ramsey B.W., Davies J., McElvaney N.G., Tullis E., Bell S.C., Dřevínek P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365(18):1663-1672. PubMed PMID: 22047557; PubMed Central PMCID: PMC3230303. 10.1056/NEJMoa1105185.